
<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Clinova</title>
	<atom:link href="http://clinova.co.uk/feed/" rel="self" type="application/rss+xml" />
	<link>http://clinova.co.uk</link>
	<description>Just another WordPress weblog</description>
	<lastBuildDate>Tue, 24 Jan 2012 15:58:02 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Meet Clinova’s leadership team in Davos</title>
		<link>http://clinova.co.uk/meet-clinova%e2%80%99s-leadership-team-at-the-world-economic-forum-annual-meeting-in-davos/</link>
		<comments>http://clinova.co.uk/meet-clinova%e2%80%99s-leadership-team-at-the-world-economic-forum-annual-meeting-in-davos/#comments</comments>
		<pubDate>Tue, 24 Jan 2012 15:44:39 +0000</pubDate>
		<dc:creator>Arsalan</dc:creator>
				<category><![CDATA[In The News]]></category>
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=1265</guid>
		<description><![CDATA[Further Information, Clinova’s leadership team led by Co-founder and Director of Research and Development, Arsalan Karim will be available to meet partners and industry leaders at the World Economic Forum annual meeting in Davos which begins on the 25th of January, 2012 and continues till the 29th of January, 2012. For further information about meeting [...]]]></description>
			<content:encoded><![CDATA[<p>Further Information,</p>
<p>Clinova’s leadership team led by Co-founder and Director of Research and Development, Arsalan Karim will be available to meet partners and industry leaders at the World Economic Forum annual meeting in Davos which begins on the 25<sup>th</sup> of January, 2012 and continues till the 29<sup>th </sup>of January, 2012.</p>
<p>For further information about meeting our team, please contact our information department with your details,</p>
<p>info@clinova.co.uk</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/meet-clinova%e2%80%99s-leadership-team-at-the-world-economic-forum-annual-meeting-in-davos/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Stemaderm ™ has successfully been granted a patent</title>
		<link>http://clinova.co.uk/clinova%e2%80%99s-novel-natural-skincare-cream-stemaderm-%e2%84%a2-has-successfully-been-granted-a-patent-the-patent-will-provide-stemaderm%e2%84%a2-with-long-term-protection-and-security-in-key-mark/</link>
		<comments>http://clinova.co.uk/clinova%e2%80%99s-novel-natural-skincare-cream-stemaderm-%e2%84%a2-has-successfully-been-granted-a-patent-the-patent-will-provide-stemaderm%e2%84%a2-with-long-term-protection-and-security-in-key-mark/#comments</comments>
		<pubDate>Tue, 10 Jan 2012 08:54:09 +0000</pubDate>
		<dc:creator>Arsalan</dc:creator>
				<category><![CDATA[Updates]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=1252</guid>
		<description><![CDATA[Further Information Stemaderm™ is a novel 100% natural skincare cream. The unique formula is based on a combination of natural ingredients that work synergistically to provide a beneficial skincare action. The patent will provide Stemaderm™ with long term protection and security in key markets. For further information about the patent, please contact our information department with your [...]]]></description>
			<content:encoded><![CDATA[<p>Further Information</p>
<p>Stemaderm™ is a novel 100% natural skincare cream. The unique formula is based on a combination of natural ingredients that work synergistically to provide a beneficial skincare action. The patent will provide Stemaderm™ with long term protection and security in key markets.</p>
<p>For further information about the patent, please contact our information department with your request,</p>
<p>info@clinova.co.uk</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/clinova%e2%80%99s-novel-natural-skincare-cream-stemaderm-%e2%84%a2-has-successfully-been-granted-a-patent-the-patent-will-provide-stemaderm%e2%84%a2-with-long-term-protection-and-security-in-key-mark/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinova appoints Andrew Lane, the present Vice-Chairman of the National Pharmacy Association as its Chief Pharmacy Officer</title>
		<link>http://clinova.co.uk/clinova-appoints-andrew-lane/</link>
		<comments>http://clinova.co.uk/clinova-appoints-andrew-lane/#comments</comments>
		<pubDate>Fri, 02 Dec 2011 09:16:06 +0000</pubDate>
		<dc:creator>davidbuck</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Updates]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=1103</guid>
		<description><![CDATA[Clinova appoints Andrew Lane, the present Vice-Chairman of the National Pharmacy Association as its Chief Pharmacy Officer. Andrew qualified at Sunderland School of Pharmacy and trained as Pharmacist with Boots the Chemist. Andrew owns the AlChem Pharmacy Group. He was elected to the National Pharmacy Association Board of Management in April 2010 to represent the South West and [...]]]></description>
			<content:encoded><![CDATA[<p>Clinova appoints Andrew Lane, the present Vice-Chairman of the National Pharmacy Association as its Chief Pharmacy Officer.</p>
<p>Andrew qualified at Sunderland School of Pharmacy and trained as Pharmacist with Boots the Chemist. Andrew owns the AlChem Pharmacy Group. He was elected to the National Pharmacy Association Board of Management in April 2010 to represent the South West and became Vice Chairman in April 2011. Andrew is the South West Regional Representative for Pharmaceutical Services Negotiating Committee and is an active member of Gloucestershire Local Pharmaceutical Committee and was recently elected to NHS Gloucestershire PEC.  He is a pharmacist member of the Primary Care Cardio Vascular Society and has interest in developing local networks of pharmacists keen to deliver services to Primary Care Commissioning organizations. Andrew will provide Clinova with strategic advise on the rollout of our new OTC products for the UK pharmacy market. He is also active in Europe as member of the Alliance Healthcare European Forum and an early advocate of Alphega Pharmacy, the virtual chain concept developed by Alliance Healthcare.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/clinova-appoints-andrew-lane/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinova has made significant progress in completing all development work relating to Clin3011 and the product is due to be launched in Europe in 2013</title>
		<link>http://clinova.co.uk/clinova-has-made-significant-progress-in-completing-all-development-work-relating-to-clin3011-and-the-product-is-due-to-be-launched-in-europe-in-2013/</link>
		<comments>http://clinova.co.uk/clinova-has-made-significant-progress-in-completing-all-development-work-relating-to-clin3011-and-the-product-is-due-to-be-launched-in-europe-in-2013/#comments</comments>
		<pubDate>Mon, 10 Oct 2011 11:21:25 +0000</pubDate>
		<dc:creator>Arsalan</dc:creator>
				<category><![CDATA[Updates]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=1261</guid>
		<description><![CDATA[Further information, Clinova aims to produce a liquid remedy that includes a X2030 as its principal ingredient. The product will be indicated to help with the management of Indigestion and Dyspepsia. Clinova’s research programme will develop the formulation and conduct all clinical development work to help launch the product globally.]]></description>
			<content:encoded><![CDATA[<p align="left">Further information,</p>
<p align="left">Clinova aims to produce a liquid remedy that includes a X2030 as its principal ingredient. The product will be indicated to help with the management of Indigestion and Dyspepsia. Clinova’s research programme will develop the formulation and conduct all clinical development work to help launch the product globally.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/clinova-has-made-significant-progress-in-completing-all-development-work-relating-to-clin3011-and-the-product-is-due-to-be-launched-in-europe-in-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinova is planning to launch its new innovative Oral Rehydration Tablets in the UK in the autumn of 2011</title>
		<link>http://clinova.co.uk/clinova-is-planning-to-launch-its-new-innovative-oral-rehydration-tablets-in-the-uk-in-the-autumn-of-2011-the-product-will-be-available-from-most-pharmacies-in-england-wales-northern-ireland-and-sc/</link>
		<comments>http://clinova.co.uk/clinova-is-planning-to-launch-its-new-innovative-oral-rehydration-tablets-in-the-uk-in-the-autumn-of-2011-the-product-will-be-available-from-most-pharmacies-in-england-wales-northern-ireland-and-sc/#comments</comments>
		<pubDate>Thu, 21 Jul 2011 16:00:32 +0000</pubDate>
		<dc:creator>clinovaadmin</dc:creator>
				<category><![CDATA[Updates]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=1042</guid>
		<description><![CDATA[Clinova plans to launch a unique Oral Rehydration Salts (ORS) effervescent tablet developed in accordance with the latest guidelines from the World Health Organisation. The usual dosage form for Oral Rehydration Salts is a sachet but Clinova’s tablet form offers significant advantages compared to existing sachet form products. Clinova’s Oral Rehydration Salts effervescent tablets are [...]]]></description>
			<content:encoded><![CDATA[<p>Clinova plans to launch a unique Oral Rehydration Salts (ORS) effervescent tablet developed in accordance with the latest guidelines from the World Health Organisation. The usual dosage form for Oral Rehydration Salts is a sachet but Clinova’s tablet form offers significant advantages compared to existing sachet form products. Clinova’s Oral Rehydration Salts effervescent tablets are a glucose-salt combination. If the body loses more fluid than it takes in e.g. in exercise or heat exhaustion, this can result in dehydration. To enable the intestines to obtain fluid from food residues, glucose and minerals are important.  The effervescent tablets replenish the water and body salts and thereby help to maintain a proper fluid balance.  This product will be available from most pharmacies in England, Wales, Northern Ireland and Scotland.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/clinova-is-planning-to-launch-its-new-innovative-oral-rehydration-tablets-in-the-uk-in-the-autumn-of-2011-the-product-will-be-available-from-most-pharmacies-in-england-wales-northern-ireland-and-sc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinova begins registration of its new insect repellent patch in Kingdom of Saudi Arabia, United Arab Emirates, Syria, Qatar and Kuwait</title>
		<link>http://clinova.co.uk/clinova-begins-registration-of-its-new-insect-repellent-patch-in-kingdom-of-saudi-arabia-united-arab-emirates-syria-qatar-and-kuwait/</link>
		<comments>http://clinova.co.uk/clinova-begins-registration-of-its-new-insect-repellent-patch-in-kingdom-of-saudi-arabia-united-arab-emirates-syria-qatar-and-kuwait/#comments</comments>
		<pubDate>Wed, 15 Jun 2011 15:30:11 +0000</pubDate>
		<dc:creator>clinovaadmin</dc:creator>
				<category><![CDATA[Updates]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=1039</guid>
		<description><![CDATA[Clinova has started the registration process of its new innovative insect repellent patch in a further 5 markets in the Middle East and North Africa region with the countries to include Kingdom of Saudi Arabia, United Arab Emirates, Syria, Qatar and Kuwait. Clinova expects the process to be completed and the products to be available [...]]]></description>
			<content:encoded><![CDATA[<p>Clinova has started the registration process of its new innovative insect repellent patch in a further 5 markets in the Middle East and North Africa region with the countries to include Kingdom of Saudi Arabia, United Arab Emirates, Syria, Qatar and Kuwait. Clinova expects the process to be completed and the products to be available in these markets by January 2012, subject to local regulatory approval.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/clinova-begins-registration-of-its-new-insect-repellent-patch-in-kingdom-of-saudi-arabia-united-arab-emirates-syria-qatar-and-kuwait/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinova begins registration of its new insect repellent patch in Jordan, Egypt and Bahrain</title>
		<link>http://clinova.co.uk/clinova-begins-registration-of-its-new-insect-repellent-patch-in-jordan-egypt-and-bahrain/</link>
		<comments>http://clinova.co.uk/clinova-begins-registration-of-its-new-insect-repellent-patch-in-jordan-egypt-and-bahrain/#comments</comments>
		<pubDate>Fri, 22 Apr 2011 16:00:45 +0000</pubDate>
		<dc:creator>clinovaadmin</dc:creator>
				<category><![CDATA[Updates]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=1036</guid>
		<description><![CDATA[Clinova has started the registration process of its new innovative insect repellent patch in the Middle East and North Africa region with the first cohort of countries to include Jordan, Egypt and Bahrain. Clinova expects the process to be completed and the products to be available in these markets by December 2011, subject to local [...]]]></description>
			<content:encoded><![CDATA[<p>Clinova has started the registration process of its new innovative insect repellent patch in the Middle East and North Africa region with the first cohort of countries to include Jordan, Egypt and Bahrain. Clinova expects the process to be completed and the products to be available in these markets by December 2011, subject to local regulatory approval.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/clinova-begins-registration-of-its-new-insect-repellent-patch-in-jordan-egypt-and-bahrain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinova supports Row Zambezi</title>
		<link>http://clinova.co.uk/clinova-supports-row-zambezi/</link>
		<comments>http://clinova.co.uk/clinova-supports-row-zambezi/#comments</comments>
		<pubDate>Mon, 21 Feb 2011 15:39:23 +0000</pubDate>
		<dc:creator>clinovaadmin</dc:creator>
				<category><![CDATA[Updates]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=899</guid>
		<description><![CDATA[Clinova has confirmed its sponsorship of the forthcoming Row Zambezi expedition whose aim is to raise money for charities supporting the provision of clean water in this remote part of Africa. In addition the Row Zambezi expedition will donate its specially built rowing boats and equipment to the Zambian Amateur Rowing Association in order to [...]]]></description>
			<content:encoded><![CDATA[<p>Clinova has confirmed its sponsorship of the forthcoming Row Zambezi<br />
expedition whose aim is to raise money for charities supporting the<br />
provision of clean water in this remote part of Africa. In addition the<br />
Row Zambezi expedition will donate its specially built rowing boats and<br />
equipment to the Zambian Amateur Rowing Association in order to create a<br />
new rowing club on Lake Kariba to bring young Zambians into the sport.</p>
<p>For further information, please visit<br />
<a href="http://www.rowzambezi.com/our-charities/">http://www.rowzambezi.com/our-charities</a></p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/clinova-supports-row-zambezi/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Stemaderm clinical study demonstrates efficacy.</title>
		<link>http://clinova.co.uk/stemaderm-clinical-study-demonstrates-efficacy/</link>
		<comments>http://clinova.co.uk/stemaderm-clinical-study-demonstrates-efficacy/#comments</comments>
		<pubDate>Sat, 28 Aug 2010 20:23:51 +0000</pubDate>
		<dc:creator>clinovaadmin</dc:creator>
				<category><![CDATA[In The News]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Updates]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=885</guid>
		<description><![CDATA[A clinical study conducted at the Department of Plastic Reconstructive and Aesthetics Surgery, University of Uludag, Turkey, has demonstrated that Stemaderm exhibits a clinically significant effect. For further information please email us at: info@clinova.co.uk]]></description>
			<content:encoded><![CDATA[<p>A clinical study conducted at the Department of Plastic Reconstructive and Aesthetics Surgery, University of Uludag, Turkey, has demonstrated that Stemaderm exhibits a clinically significant effect.</p>
<p>For further information please email us at:</p>
<p>info@clinova.co.uk</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/stemaderm-clinical-study-demonstrates-efficacy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Volcanic ash may cause respiratory problems</title>
		<link>http://clinova.co.uk/volcanic-ash-may-cause-respiratory-problems/</link>
		<comments>http://clinova.co.uk/volcanic-ash-may-cause-respiratory-problems/#comments</comments>
		<pubDate>Sun, 18 Apr 2010 11:41:01 +0000</pubDate>
		<dc:creator>clinovaadmin</dc:creator>
				<category><![CDATA[Updates]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=727</guid>
		<description><![CDATA[The Icelandic volcano has sent an enormous cloud of Volcanic ash across northern Europe, grounding aircraft across continent. Volcanic ash consists of small particles of volcanic rock. It is light grey to black and can be as fine as talcum powder. During a volcanic eruption, the ash can be breathed deep into the lungs and cause [...]]]></description>
			<content:encoded><![CDATA[<p>The Icelandic volcano has sent an enormous cloud of Volcanic ash across northern Europe, grounding aircraft across continent.</p>
<p>Volcanic ash consists of small particles of volcanic rock. It is light grey to black and can be as fine as talcum powder. During a volcanic eruption, the ash can be breathed deep into the lungs and cause irritation even in healthy people</p>
<p>Volcanic ash can be especially harmful to people with respiratory conditions lung disease such as asthma and chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. Exposure to particulate air pollution can trigger asthma attacks and cause wheezing, coughing, and respiratory irritation in individuals with sensitive airways.</p>
<p>WHO spokesman Daniel Epstein said the microscopic ash is potentially dangerous for people when it starts to reach the Earth because inhaled particles can enter the lungs and cause respiratory problems.</p>
<p>&#8220;We&#8217;re very concerned about it,&#8221; Epstein said. &#8220;These particles when inhaled can reach the peripheral regions of &#8230; the lungs and can cause problems — especially for people with asthma or respiratory problems.&#8221; He also said Europeans who go outside might want to consider wearing a mask.</p>
<p>Whilst volcanic ash is suspended in the air, it is vital that the population exposed protects themselves by wearing masks. For protection against volcanic ash, high-efficiency, light-weight disposable masks/respirators are appropriate. The mask must provide protection at the highest concentration the person will experience. Suitable disposable masks are ‘CE’ marked to show that the design has been tested to a recognised standard such as Covaflu FFP3 face mask.</p>
<p>For the public, use of masks is only necessary whilst the levels of suspended dust are above background levels. For those involved in clean-up operations, garden maintenance or even people who are cleaning houses and property, masks should be worn at all times whilst the ash is mobile in the atmosphere.</p>
<p>The following guidelines will protect your respiarory health, and should be followed especially by those at highest risk, children, pregnant women, the elderly, and those with chronic lung diseases.</p>
<p>1 Stay indoors.</p>
<p>2 Do not smoke</p>
<p>3 Drink plenty of fluids to loosen mucus and help you cough.</p>
<p>4 Refrain from all outdoor exercise if particle pollution is visible.</p>
<p>5 If you take medications, put them in a convenient place. It is important to continue taking your medicines. Medications you need for an acute episode should be readily available.</p>
<p>6 Assume that your lung condition may deteriorate and contact your physician as soon as any problem develops. Do not allow a respiratory condition to linger, especially if there is a high concentration of ash particles.</p>
<p>7 Utilize air quality monitoring systems to determine the safety of the air quality in your area each day.</p>
<p>8 A mask with such Covaflu FFP3 rating is ideal for volcanic ash protection.</p>
<p>While these suggestions are intended especially for persons suffering from respiratory conditions (asthma, emphysema, bronchitis), they are also useful for normally healthy people during episodes of volcanic haze.</p>
<p style="text-align: center;">You can purchase these now online at<a href="http://www.chemistdirect.co.uk/search_results.php?q=covaflu"><br />
<img class="aligncenter size-full wp-image-730" title="Buy Now" src="http://clinova.co.uk/wp-content/uploads/2010/04/logo_chemistdirect1.gif" alt="" width="234" height="53" /></a></p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/volcanic-ash-may-cause-respiratory-problems/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

